康泰生物(300601.SZ)：吸附无细胞百白破(组分)联合疫苗(成人青少年及儿童用)临床试验申请获得受理

Core Viewpoint - Kangtai Biological (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd., received a notice of acceptance from the National Medical Products Administration for the clinical trial application of an acellular pertussis-diphtheria-tetanus combined vaccine for adults, adolescents, and children [1] Group 1 - The clinical trial application for the acellular pertussis-diphtheria-tetanus combined vaccine has been accepted, indicating progress in vaccine development [1] - The vaccine is intended for use in adults, adolescents, and children, aiming to elicit an immune response to prevent pertussis, diphtheria, and tetanus [1]